The complaint filed against the NASDAQ-listed company claims that between January 14, 2025, and April 26, 2026, Erasca failed to disclose critical risks associated with its ERAS-0015 candidate. According to the filing, preclinical data for the drug relied on improper comparisons to RevMed, which allegedly placed Erasca in jeopardy of violating patent and trade secret protections. The suit argues that these omissions rendered the company's public statements regarding its operations materially misleading.
Those interested in the litigation or seeking to discuss their legal standing can contact the Law Offices of Howard G. Smith in Bensalem, Pennsylvania. While the firm is actively seeking a lead plaintiff, investors are not required to take immediate action to remain members of the class. Legal counsel can be reached via telephone at 215-638-4847 or through their official website.
Comments (0)
No comments yet. Be the first!